Glowing Nanoparticles Exposed Hidden Cancer-Protein Behavior that Could Reshape Drug Screening
A Broad Institute team led by Sam Peng introduced upconverting nanoparticle probes that remain luminescent for minutes to hours, enabling continuous single‑molecule imaging of cancer‑related receptors in living cells. Using these probes, they captured real‑time dimerization dynamics of EGFR, HER2 and HER3, revealing that mutant EGFR forms unusually stable dimers even without external stimulation. The study, published in Cell, demonstrates how this high‑resolution, long‑term tracking can uncover hidden protein behaviors that traditional dyes miss. Researchers suggest the method could transform drug‑screening assays by visualizing therapeutic effects on individual receptors.
Protein Degraders Gain Speed as Arvinas Scores Landmark Approval
Arvinas received FDA approval for Veppanu, the first PROTAC therapy, marking a milestone for protein degraders. The drug showed modest benefit in a phase 3 trial, with the clearest effect in patients carrying ESR1 mutations, prompting the company to lay off...
Theranostic Fiber with Micro‑Wrinkles Promises Real‑Time Health Monitoring
Scientists Meng, Zou and Lv introduced a multifunctional theranostic fiber that integrates micro‑wrinkles to sense physiological signals, deliver treatment and wirelessly transmit data. The work, published in npj Flexible Electronics, could reshape personalized healthcare and human‑machine interfaces.
Everads Therapy Publishes First-in-Human Data on Suprachoroidal Injector
Everads Therapy announced the publication of first-in-human trial data for its suprachoroidal injector, demonstrating safety, tolerability and rapid posterior drug distribution in patients with diabetic macular edema. The results, appearing in Ophthalmology Science, were showcased at the ARVO 2026 meeting,...
Module 4, Section 2: All About Assays
The Module 4, Section 2 briefing provides a concise overview of modern assay platforms used in early‑stage drug discovery. It references key literature on PRMT5 fragment‑based screening that produced the MRTX1719 candidate, as well as thermal‑shift, surface plasmon resonance (SPR), and polymerase...
Needle-Free Diabetes Care: 6 Devices that Painlessly Monitor Blood Sugar
Needle‑free glucose monitors are moving from research labs to commercial shelves, with six innovative devices highlighted for their non‑invasive approaches. Abbott’s FreeStyle Libre remains the market leader for interstitial sensing, while newcomers such as Occuity Indigo, D‑Pocket, Light Touch Technology,...
PCI Adds US Sterile Fill/Finish Capabilities Through $1B Global Expansion Drive
PCI Pharma Services announced a $1 billion global expansion, allocating $100 million to upgrade its San Diego campus with a high‑speed isolator line that will more than double its prefilled syringe capacity. The company also launched a GMP‑ready isolator vial and lyophilization line...
BEAM Wins TIME 100, Delivers First Gene Base Editing Cure
Congrats to $BEAM on being named as one of @TIME’s 100 most influential & innovative companies that are shaping the world & our future. @beamtx’s leading Gene Editing platform - Base editing, has achieved a significant milestone when KJ Muldoon...
Drug Side Effects Are Often the Main Effects
The article argues that drug side effects are not peripheral accidents but integral parts of a medication’s primary pharmacological action. It explains that the same biochemical pathways that deliver therapeutic benefits also generate adverse outcomes, using aspirin, blood‑pressure agents, and...
Regulatory Submissions with Real-World Evidence: Successes, Challenges, and Lessons Learned - 09/23/2025
In a September 23, 2025 speech, FDA Principal Deputy Commissioner Sara Brenner outlined how real‑world evidence (RWE) has been used to support regulatory decisions and announced the agency‑wide FDA‑RWE‑ACCELERATE initiative. She highlighted recent examples from CDER, CBER and CDRH, and introduced Sentinel 3.0,...
Speed 'Training' Prepares Bacteria for Complex Tasks, Like Munching Plastics
Researchers at the National University of Singapore unveiled Lytic Selection and Evolution (LySE), a phage‑based platform that can rapidly evolve large gene clusters up to 40 kb. In a proof‑of‑concept, LySE boosted a five‑gene pathway enabling E. coli to consume ethylene glycol,...
First FDA ODAC Meeting without Pazdur Highlights Conceptual Challenges with Trial
The FDA’s Oncology Drugs Advisory Committee (ODAC) convened for the first time in nine months to review two AstraZeneca cancer therapies. The panel voted 6‑3 against approving camizestrant, an oral SERD for HER2‑negative advanced breast cancer, citing the trial’s failure...
Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
Sonire Therapeutics announced the launch of SUNRISE‑II, its first U.S. clinical trial evaluating a proprietary high‑intensity focused ultrasound (HIFU) system for pancreatic cancer. The study will enroll roughly 10 patients to assess safety and feasibility. The inaugural patient was treated...
Celcuity Reports the P-III (VIKTORIA-1) Trial Data on Gedatolisib Combination for HR+/HER2- PIK3CA Mutant Advanced Breast Cancer
Celcuity announced phase‑III VIKTORIA‑1 data showing that gedatolisib combined with fulvestrant, with or without palbociclib, achieved a statistically significant improvement in progression‑free survival (PFS) versus the alpelisib‑fulvestrant standard of care in HR+/HER2‑ advanced breast cancer patients harboring PIK3CA mutations. The...
Summit Shares Descend as PD-1/VEGF Asset Misses Early Survival Mark
Summit Therapeutics announced that its anti‑PD‑1/VEGF bispecific, ivonescimab, failed to meet the interim progression‑free survival threshold in the Phase 3 HARMONi‑3 trial for squamous NSCLC. The miss triggered a 26% plunge in Summit’s share price, closing at $16.12. An independent data...
Drugmaker AbbVie Chooses North Carolina for $1.4B Manufacturing Campus
AbbVie announced a $1.4 billion investment to build a 185‑acre manufacturing campus in Durham, North Carolina, targeting its immunology, neuroscience and oncology portfolios. The site will create 734 jobs over four years, incorporate AI‑driven production tools, and be operational by the...
UCB Captures Candid in $2.2B Autoimmune Deal as Pharma’s M&A Train Chugs Along
UCB announced a $2 billion acquisition of Candid Therapeutics, adding a pipeline of T‑cell engager drugs aimed at autoimmune and inflammatory diseases. The deal also includes up to $200 million in milestone payments and is expected to close by Q3 2026. Candid’s...
How a Vision-Restoring Gene Therapy Proved that We Can Treat Inherited Diseases
Luxturna, the first FDA‑approved gene‑augmenting therapy for inherited retinal disease, received the 2026 Breakthrough Prize after restoring sight to patients with Leber’s congenital amaurosis type 2. Developed by Spark Therapeutics founders Katherine High, Jean Bennett and surgeon Albert Maguire, the treatment...
Obesity Ends Oncology’s Long Reign as Top Contributor to Biopharma Pipeline Value
Deloitte’s 2025 pipeline analysis shows obesity overtaking oncology as the top value‑generating therapeutic area, accounting for 25% of total pipeline worth. Eli Lilly and Novo Nordisk dominate the obesity segment, together holding roughly 96% of its assigned value. GLP‑1/GIP agonists are driving...
OneSource Notches a Second Generic Semaglutide Approval in Canada, Through Partner
Canada approved its second generic version of Ozempic (semaglutide) through Apotex, which partnered with Orbicular Pharmaceutical Technologies and India‑based CDMO OneSource Specialty Pharma. OneSource handled end‑to‑end manufacturing, leveraging its FDA‑approved Bengaluru facility, while Orbicular led product development. The approval follows...
UC Berkeley Convenes Experts to Probe the Ultimate Limits of Human Longevity
On May 2, 2026, UC Berkeley hosted a conference that brought together researchers and innovators to explore how long humans could theoretically live. The gathering signals growing academic and public focus on life‑extension strategies within the biohacking community.
FDA Greenlights First Ibogaine Trial as Hype Eclipses Limited Data
The U.S. Food and Drug Administration announced it will permit the first clinical trial of ibogaine, a psychedelic derived from a West African shrub, after President Donald Trump highlighted the drug at a White House event. Researchers caution that the...
A Mechanism Linking Protein Aggregation to STING Activation and Inflammation in the Aging Brain
Researchers identified S‑nitrosylation of the immune sensor STING at cysteine‑148 as a key driver of neuroinflammation in Alzheimer’s disease. The modified protein, SNO‑STING, was abundant in human Alzheimer’s brains, cultured microglia, and mouse models. Blocking this chemical change reduced microglial...
Andalusia Unveils Ruthenium‑Uracil Nanoparticle Coating to Combat Hospital Superbugs
A team from the Instituto de Investigaciones Químicas, backed by the CSIC and the University of Sevilla, has created a ruthenium‑uracil nanoparticle that eliminates Staphylococcus aureus in lab tests. The breakthrough, funded by the Andalusian Ministry of University, Research and...
FDA Grants 510(k) Clearance to TaeWoong Medical for Spaxus EUS Stent
TaeWoong Medical received FDA 510(k) clearance for its Niti‑S Spaxus Stent, a fully covered, self‑expanding metallic device used in endoscopic ultrasound (EUS)‑guided drainage. The stent is approved for draining symptomatic pancreatic pseudocysts, walled‑off necrosis larger than 6 cm, and for gallbladder...
What Is Your AI Drug Repurposing Strategy Missing?
The article argues that AI‑driven drug repurposing for oncology often fails because models are fed fragmented, noisy data despite abundant datasets. It stresses that more data alone won’t improve outcomes; instead, high‑quality, curated, structured data—such as knowledge graphs linking genes,...
EU Backs Itvisma Gene Therapy for Spinal Muscular Atrophy
European regulators have issued a positive opinion on Itvisma, Novartis' onasemnogene abeparvovec gene therapy for spinal muscular atrophy (SMA). The Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorisation on 23 April 2026, pending final approval by the European Commission....
Vantrexa Sets High Standards for Retatrutide Research Materials in Metabolic Studies
Vantrexa, a professional laboratory supplier, is now offering research‑grade Retatrutide (LY3437943), a triple‑agonist targeting GLP‑1, GIP and glucagon receptors, for metabolic studies. The company employs advanced solid‑phase peptide synthesis and rigorous in‑house plus third‑party HPLC/LC‑MS testing, achieving purity levels above...
Rhythm Pharmaceuticals Reports the EC Approval of Imcivree (Setmelanotide) for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that the European Commission has granted marketing authorization for Imcivree (setmelanotide) to treat acquired hypothalamic obesity in patients aged four years and older. The approval is based on the Phase III TRANSCEND trial, which enrolled 120 participants...
Novo Nordisk to Launch Ozempic for Type 2 Diabetes in US
Novo Nordisk will launch an oral version of Ozempic in the United States, following FDA approval that marks the first oral GLP‑1 drug cleared for both blood‑sugar control and cardiovascular risk reduction. The tablets, available in 1.5 mg, 4 mg and 9 mg...
Novel Wheat Hybrids Increase Resistance to Major Fungal Disease by up to 70%
Researchers have transferred a novel resistance locus from the wild weed Elymus repens into wheat, creating hybrids that slash Fusarium head blight (FHB) infection by up to 70%. The new locus, named Fhb.Er‑1StL, showed a 69% reduction in diseased spikelets...
Arvinas and Pfizer Report the US FDA Approval of Veppanu (Vepdegestrant) for ESR1-Mutated Breast Cancer
The U.S. FDA has approved Veppanu (vepdegestrant) for adults with ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer who have received at least one line of endocrine therapy. The approval follows the Phase III VERITAC‑2 trial, which compared Veppanu to fulvestrant...
MAHA Vs. The FDA: Dredging up Old Anti-Regulation Revisionist History
A new essay in Science-Based Medicine denounces the “health‑freedom” narrative that seeks to dismantle the FDA. It traces the agency’s authority back to the 1962 Kefauver‑Harris amendment, which linked drug approval to rigorous safety and efficacy trials. The author dismantles...
65 % of Eligible Lung Cancer Patients Do Not Receive the Most Appropriate Targeted Therapies, Diaceutics Report Finds
Diaceutics’ 2026 Clinical Practice Gaps report shows that 65% of U.S. patients with advanced non‑small cell lung cancer still miss the most appropriate targeted therapy, a figure unchanged since 2019. While biomarker testing has improved, the biggest loss now occurs...
Artificial Retina Uses Biological Liquid Medium for Direct-to-Display ‘Vision’
Italian researchers led by Prof. Thomas M. Brown unveiled BIOPIX, a bio‑electronic hybrid retina emulator that embeds organic photodetectors in a liquid Ames medium. The proof‑of‑concept includes a 2 × 2 cone‑type array for colour and a 4 × 4 rod‑type array for grayscale,...
Novel Bioprinting Method Lays the Foundation for Personalised Regenerative Medicine
Researchers in Italy unveiled a solid‑electronics, liquid‑electrolyte sensor array that mimics retinal function, marking a proof‑of‑concept for bio‑integrated vision devices. A cell‑free hydrogel delivering extracellular vesicles showed efficacy in repairing intrauterine adhesions and restoring fertility in preclinical studies. An analysis...
Glowing Probe Detects Multiple Antibiotics with Just a Smartphone
Researchers in Italy unveiled a proof‑of‑concept sensor array that blends solid‑state electronics with a liquid electrolyte, effectively mimicking biological vision and allowing a smartphone to detect multiple antibiotics via fluorescence. In parallel, a heat‑resistant polyamide was engineered to emit pure...
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate
May’s FDA docket is light, but the decisions on four high‑profile drugs could reshape market dynamics. Argenx is seeking to broaden Vyvgart’s label to seronegative myasthenia gravis patients, potentially adding 11,000 new users. AstraZeneca and Daiichi Sankyo aim to secure...
Viewpoint: How ‘Health Care Guru’ Joe Rogan Circumvented the FDA’s Skepticism on Psychedelics
Joe Rogan directly messaged President Donald Trump about the therapeutic potential of psychedelics, prompting the president to sign an executive order that fast‑tracks FDA review of these drugs. The order creates a priority‑voucher system that accelerates approvals for psychedelic manufacturers,...
Hidden Ingredient in GLP-1 Tablets Raises New Gut Health Questions
Oral semaglutide tablets rely on the absorption enhancer SNAC (salcaprozate sodium) to cross the stomach lining, but only 0.4%‑1% of the drug reaches the bloodstream. A 21‑day rat study published in the Journal of Controlled Release found that the majority...
FDA Clears GSK’s Gepotidacin, First New Oral UTI Antibiotic in 30 Years
The U.S. Food and Drug Administration has approved GSK’s gepotidacin (Blujepa) for uncomplicated urinary tract infections in females aged 12 and older, marking the first new oral antibiotic class for this indication in nearly 30 years. The decision follows pivotal...
Eli Lilly Inks $2.25 B Profluent Deal to Fast‑track AI‑driven Gene‑therapy Platform
Eli Lilly signed a research agreement worth up to $2.25 billion with AI protein‑design firm Profluent to develop next‑generation gene‑therapy candidates using AI‑engineered recombinases. The deal leverages cash from Lilly’s obesity drug franchise and adds to a string of multi‑billion‑dollar gene‑therapy...
Mitochondrial Dysfunction Drives Frailty; Biomarkers Needed for Precision Therapy
The mitochondrial side of frailty "Mitochondrial dysfunction lies at the intersection of musculoskeletal, metabolic, and immune changes underpinning frailty. While integrative biomarker panels have defined metabolic signatures, early diagnosis and personalized therapies remain unmet needs. Longitudinal studies are required to establish...
Hantaviruses Counteract Cell Interferon (IFN) Defense
Cells produce interferon when they are infected by viruses. It regulates antiviral responses. Cells produce interferon when infected with hantaviruses. Depending on the hantavirus, it may produce antagonists to counter the defense. And the convention is IFN, not INF. IYKYK
Study Links Oleic Acid to Faster Pancreatic Cancer, Fish Oil Cuts Risk 50%
Yale scientists reported that the type of dietary fat, not the total amount, drives pancreatic cancer development. Oleic acid—common in olive oil—accelerated tumor growth in mice, while omega‑3‑rich fish oil reduced disease burden by 50%, a finding that could reshape...
Reflecting on Craig Venter’s Pioneering Genome Era
I enjoyed this remembrance of Craig Venter and the early days of the genome project by @StevenSalzberg1. https://t.co/ggzbrvWlAk
Pharma Embraces AI, Yet Breakthrough Drugs Remain Elusive
JUST IN: The pharmaceutical industry is adopting AI, but new drug discovery through it remains elusive.
BioMarin Shows Long‑Term VOXZOGO Gains in Height, Arm Span and Bone Health
BioMarin Pharmaceutical announced new long‑term data for VOXZOGO® at the Pediatric Endocrine Society’s 2026 Annual Meeting, reporting up to 13.6 cm additional height after eight years, improved arm‑span Z‑scores and stable bone mineral density. The findings reinforce the drug’s position as...
Queensland Funds Research Into Cell-Based Therapies for Traumatic Brain Injury
The Queensland Government has pledged A$5.5 million (about US$3.6 million) over three years to the Cure TBI initiative, a research programme focused on cell‑based therapies for traumatic brain injury. Backed by the National Injury Insurance Scheme, Queensland (NIISQ), the effort will be...
UCB to Acquire Candid Therapeutics for $2 B, Adding T‑Cell Engager Platform to Immunology Portfolio
UCB announced a definitive agreement to acquire privately held Candid Therapeutics for $2 billion in cash, with up to $200 million in future milestones. The deal adds Candid’s lead bispecific antibody, cizutamig, and a pipeline of multi‑specific T‑cell engagers to UCB’s immunology...